Compare AbbVie Inc (ABBV) vs Jabil Inc (JBL) Price & Performance

AbbVie (ABBV) trades at $252.61, down 0.84% on the day, with a bullish technical outlook supported by moving averages and strong support at $248. The company reported revenue of $61.16B in 2025, with EPS beats in recent quarters, though net income margin has trended down to 5.79%. Key growth drivers Skyrizi and Rinvoq are offsetting Humira declines, with positive clinical updates like the Phase 2 ELAHERE data at SGO 2026.

The stock offers a compelling buy case with a consensus price target of $266.33 (5.4% upside) and strong analyst support (68% buy ratings). However, risks include patent cliffs in the 2030s, high debt levels, and margin pressure. Dividend growth is recovering, supporting income investors, but execution on pipeline assets remains critical for sustained expansion.

JBL trades at $338.22, down 0.9% today, with technical indicators showing a bearish trend near support at $333. The stock has demonstrated strong earnings momentum, beating estimates for three consecutive quarters, and benefits from AI infrastructure demand driving revenue growth. Analyst consensus is split evenly between Buy and Hold ratings with a $436.50 price target suggesting significant upside potential.

The outlook remains positive due to AI-driven growth and margin expansion, though high valuation multiples and competitive pressures present risks. Recent manufacturing expansion in India and hyperscaler customer wins support long-term growth, but investors should monitor execution against elevated expectations.